PNV 1.47% $2.07 polynovo limited

Ann: US Dept of Defence & access to other Federal contracts, page-57

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 17,186 Posts.
    lightbulb Created with Sketch. 2426
    Got to say, I am fully hoping for a pull back and would be happy to get some more sub $1.
    But seriously, I doubt I'll get the opportunity now. With CE approval, UK sales, breast implant development announcements and further sales milestones all likely in the next 6 months there will be plenty to keep nomentum going. I wouldn't be at all surprised to see it over $1.20 when CE approval is announced.

    Honestly I never thought it would go up this fast, and until the recent announcements I thought it was pretty expensive. But with $1m in sales for April already, Aus & NZ markets going well with government rebates to patients, now Medicare and Medicaid in the US have stepped up with patient reimbursements, European distributor ready to go with hundreds of clients... surely its pure gold. The thing that really sticks in my mind was the frequency of early re-ordering from hospitals that have used it. Even the company was surprised. That tells you how well it works, how useful it is, and how much surgeons love it.

    I don't know for sure why it works so much better than other products. But the fact that it does is enough.
    Last edited by whytee: 03/05/19
 
watchlist Created with Sketch. Add PNV (ASX) to my watchlist
(20min delay)
Last
$2.07
Change
0.030(1.47%)
Mkt cap ! $1.429B
Open High Low Value Volume
$2.11 $2.12 $2.05 $2.783M 1.335M

Buyers (Bids)

No. Vol. Price($)
5 19976 $2.05
 

Sellers (Offers)

Price($) Vol. No.
$2.07 9633 3
View Market Depth
Last trade - 16.10pm 08/11/2024 (20 minute delay) ?
PNV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.